Home | Register | Login | Inquiries | Alerts | Sitemap |  


Advanced Search
JKM > Volume 35(3); 2014 > Article
Han and Yang: A Review on Korean Medicine and Personalized Medicine: Syndrome-based Personalized Medicine on the Basis of Syndrome Differentiation and Treatment

Abstract

Objectives:

This study aimed to review the characteristics of personalized medicine and Korean medicine, and the correlation between personalized medicine and Korean medicine.

Methods:

We investigated various studies in PubMed, Scopus and domestic Korean medicine journals. In addition, we discussed the topic based on literature.

Results:

Western medicine developed as evidence-based medicine. However, its limitations are being reached, so a new paradigm of medicine is needed. As a result, personalized medicine has appeared. Recently, through the development of human genomics, personalized medicine has been researched on the basis of individual genetic characteristics. Korean medicine has developed with a unique holistic approach and treats not the disease itself but the patient’s body. Its characteristic is well expressed through syndrome differentiation and treatment. Syndrome differentiation represents the nature of person-centered medicine and becomes the root of personalized medicine.

Conclusions:

Compared with genome-based personalized medicine of Western medicine, Korean medicine could be classified as syndrome-based personalized medicine. It would be great to apply this characteristic to clinical practices.

참고문헌

1. Ahn HS. Introduction to Evidence-based Medicine. Journal of Korean Society of Quality Assurance in Health Care. 2005; 12:2. 9–16.
crossref

2. Lim YC. A Critical Contemplation on ‘Personalized Medicine’ of Modern Medicine. The Korean Association for Philosophy of Medicine. 2012; 13:135–162.


3. Hong KW, Oh B. Overview of personalized medicine in the disease genomic era. BMB Rep. 2010; 43:10. 643648
crossref pmid

4. Lee SW, Lee KB, Kang JW, Choi JH, Oh JH. Trends in Personalized Medicine Research, Communications of the Korean Institute of Information Scientists and Engineer. 2011; 29:4. 19–25.


5. Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, et al. Clinical Pharmacogenetics and Potential Application in Personalized Medicine. Curr Drug Metab. 2008; 9:8. 738–84.
crossref pmid

6. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010; 363:4. 301–4.
crossref pmid

7. Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. Nature. 2009; 461:7265. 724–6.
crossref pmid

8. Fung EY, Smyth DJ, Howson JM, Cooper JD, Walker NM, Stevens H, et al. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun. 2009; 10:2. 188–91.
crossref pmid

9. Dai J, Fang J, Sun S, Chen Q, Cao H, Zheng N, et al. ZHENG-Omics Application in ZHENG Classification and Treatment: Chinese Personalized Medicine. Evid Based Complement Alternat Med. 2013; 2013:235969
crossref pmid pmc

10. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992; 268:17. 2420–5.
crossref pmid

11. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996; 312:7023. 71–2.
crossref pmid pmc

12. Rosenberg W, Donald A. Evidence based medicine: an approach to clinical problem-solving. BMJ. 1995; 310:6987. 1122–6.
crossref pmid pmc

13. Tonelli MR. The philosophical limits of evidence-based medicine. Acad Med. 1998; 73:12. 1234–40.
crossref pmid

14. Goldman JJ, Shih TL. The limitations of evidence-based medicine--applying population-based recommendations to individual patients. Virtual Mentor. 2011; 13:1. 26–30.
crossref pmid

15. Jain KK. Textbook of Personalized Medicine. New York: Springer;2009. p. 1–136.
crossref

16. Straus SE, McAlister FA. Evidence-based medicine: a commentary on common criticisms. CMAJ. 2000; Oct. 3. 163:7. 837–41.
pmid pmc

17. Cohen AM, Stavri PZ, Hersh WR. A categorization and analysis of the criticisms of Evidence-Based Medicine. Int J Med Inform. 2004; 73:1. 35–43.
crossref pmid

18. Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 2001; 19:12. 491–6.
crossref pmid

19. Ray O. The revolutionary health science of psychoendoneuroimmunology: a new paradigm for understanding health and treating illness. Ann N Y Acad Sci. 2004; 1032:35–51.
crossref pmid

20. Yan Q. Toward the integration of personalized and systems medicine: challenges, opportunities and approaches. Personalized Medicine. 2011; 8:1. 1–4.
crossref

21. Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy. 2008; 28:8. 992–8.
crossref pmid

22. Novelli G. Personalized genomic medicine. Intern Emerg Med. 2010; 5:1. 81–90.
crossref pmid

23. Lee SW, Lee KB, Kang JW, Choi JH, Oh JH. Trends in Personalized Medicine Research, Communications of the Korean Institute of Information Scientists and Engineer. 2011; 29:4. 19–25.


24. Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM. Impact of genomics on drug discovery and clinical medicine. QJM. 2000; 93:7. 391–423.
crossref pmid

25. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007; 447:7145. 661–78.
crossref pmid pmc

26. Gispen WH, Adan RAH. Preface. Eur J Pharmacol. 2000; 410:2–3. 105
crossref

27. Shin JG, Cha IJ. Pharmacogenetics: A Principle for the Personalized Pharmacotherapy. Inje Medical Journal. 2002; 23:2. 71–83.


28. Yan Q. Pharmacogenomics in Drug Discovery and Development : From Bench to Bedside. Clifton:Methods Mol Biol. 2008; 448:5–7.


29. Zhang A, Sun H, Wang P, Han Y, Wang X. Future perspectives of personalized medicine in traditional Chinese medicine: a systems biology approach. Complement Ther Med. 2012; 20:1–2. 93–9.
crossref pmid

30. Wang X, Sun H, Zhang A, Sun W, Wang P, Wang Z. Potential role of metabolomics apporoaches in the area of traditional Chinese medicine: as pillars of the bridge between Chinese and Western medicine. J Pharm Biomed Anal. 2011; 55:5. 859–68.
crossref

31. Kim WH. Hanuihak Wonron. Seoul: Seongbosa;2001. p. 32–34.


32. Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther. 2007; 81:6. 807–16.
crossref pmid

33. Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013; 14:55
crossref pmid pmc

34. Franzel B, Schwiegershausen M, Heusser P, Berger B. Individualised medicine from the perspectives of patients using complementary therapies: a meta-ethnography approach. BMC Complement Altern Med. 2013; 13:124
crossref

TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
PubReader  PubReader
Download Citation  Download Citation
  E-Mail
  Print
Share:      
METRICS
0
Crossref
2,258
View
16
Download
Editorial office contact information
3F, #26-27 Gayang-dong, Gangseo-gu Seoul, 157-200 Seoul, Korea
The Society of Korean Medicine
Tel : +82-2-2658-3614   Fax : +82-2-2658-3631   E-mail : skom1953@daum.net
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
powerd by m2community